<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01361646</url>
  </required_header>
  <id_info>
    <org_study_id>LG-GDCL001</org_study_id>
    <nct_id>NCT01361646</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of LC350189</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Life Sciences</source>
  <brief_summary>
    <textblock>
      This will be a dose block-randomized, double-blind, active and placebo controlled, single and
      multiple dosing, dose-escalation study to evaluate tolerability, safety and pharmacokinetic /
      pharmacodynamic characteristics. Adverse events, physical examinations, vital signs, ECG and
      laboratory tests will be conducted for safety/tolerability evaluation and serial blood
      samples and urine collections for pharmacokinetic and pharmacodynamic evaluations will be
      conducted at specified time points.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events of LC350189</measure>
    <time_frame>7 days(plus or minus 1 day)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>3days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>3days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">129</enrollment>
  <condition>Hyperuricemia</condition>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>LC350189</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Febuxostat</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LC350189</intervention_name>
    <description>Single Ascending Dose: 10, 25, 50, 100, 200, 400, 600mg Multifle Ascending Dose: 100, 200, 400, 600, 800mg</description>
    <arm_group_label>LC350189</arm_group_label>
    <arm_group_label>Febuxostat</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male subjects between the ages of 20 and 50 years at screening

          2. Subjects with Body Mass Index (BMI) between 18.0 (inclusive) and 27.0 kg/m2
             (exclusive); and a total body weight between 55 kg (inclusive) and 90 kg (exclusive).
             â˜ž BMI (kg/m2) = body weight (kg)/ {height (m)}2.

          3. Subject is informed of the investigational nature of this study and voluntarily agrees
             to participate in this study and signs an Institutional Review Board (IRB) - approved
             informed consent prior to performing any of the screening procedures.

          4. Findings within the range of clinical acceptability in medical history and physical
             examination, and laboratory results within the laboratory reference ranges for the
             relevant laboratory tests
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung Sang Yu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2011</study_first_submitted>
  <study_first_submitted_qc>May 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2011</study_first_posted>
  <last_update_submitted>June 10, 2013</last_update_submitted>
  <last_update_submitted_qc>June 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

